PriceTargets.com logo

ALK-Abelló A/S - AKBLF Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$22.35 As of 12/20/2024 12:25 PM ET
▲ +0.3 (1.36%)

This chart shows the closing price for AKBLF by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New ALK-Abelló A/S Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for AKBLF and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for AKBLF

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for ALK-Abelló A/S in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $22.35.

This chart shows the closing price for AKBLF for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 contributing investment analysts is to n/a stock in ALK-Abelló A/S. This rating has held steady since September 2024, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
6/30/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
9/28/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/27/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/26/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/24/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/22/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/21/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/21/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
10/4/2023DNB MarketsUpgradeHold ➝ Buy
6/9/2023DanskeUpgradeHold ➝ Buy
5/10/2023DanskeUpgradeSell ➝ Hold
4/18/2023DanskeDowngradeBuy ➝ Sell
4/18/2023DNB MarketsDowngradeBuy ➝ Hold
11/8/2022SEB EquitiesUpgradeHold ➝ Buy140.00
11/1/2022DanskeDowngradeBuy ➝ Hold
9/13/2022Bryan, Garnier & CoInitiated CoverageBuy160.00
1/19/2022DNB MarketsUpgradeHold ➝ Buy$3,500.00
1/19/2022DanskeUpgradeHold ➝ Buy$3,600.00
11/12/2021DNB MarketsDowngradeBuy ➝ Hold
(Data available from 12/21/2019 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/25/2024
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/24/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/24/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/23/2024
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/22/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/22/2024
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/21/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/21/2024

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
ALK-Abelló A/S logo
ALK-Abelló A/S operates as an allergy solutions company in Europe, North America, and internationally. Its product portfolio includes GRAZAX/GRASTEK, RAGWITEK/RAGWIZAX, ACARIZAX/ODACTRA, MITICURE, CEDARCURE, and ITULAZAX/ITULATEK for treatment of allergic rhinitis and allergic asthma. The company offers allergy immunotherapy products in the form of injections, sublingual drops, and tablets for the treatment of various allergies, including grass, ragweed, house dust mite, Japanese cedar, tree, and food. It also provides consumer healthcare solution, which include Digital eco-system, a platform which connect and engages with allergy sufferers in the disease journey through tools and e-commerce offerings that supports, guidance and relief, and smoothing the path to allergy immunotherapy treatment. In addition, the company offers diagnostic allergy solutions through testing by skin prick test or blood test; and emergency treatment, such as intra-muscular injection of adrenaline for the treatment of acute life-threatening allergic reactions, including Anaphylaxis. The company has a collaboration with Torii Pharmaceutical Co., Ltd. to develop, market and distribute allergy immunotherapy tablet for the treatment of grass pollen allergy. ALK-Abelló A/S was founded in 1923 and is headquartered in Horsholm, Denmark.
Read More

Today's Range

Now: $22.35
Low: $22.35
High: $22.35

50 Day Range

MA: $23.24
Low: $22.05
High: $26.50

52 Week Range

Now: $22.35
Low: $17.31
High: $27.03

Volume

100 shs

Average Volume

559 shs

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of ALK-Abelló A/S?

The following Wall Street research analysts have issued reports on ALK-Abelló A/S in the last twelve months:
View the latest analyst ratings for AKBLF.

What is the current price target for ALK-Abelló A/S?

0 Wall Street analysts have set twelve-month price targets for ALK-Abelló A/S in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for ALK-Abelló A/S in the next year.
View the latest price targets for AKBLF.

What is the current consensus analyst rating for ALK-Abelló A/S?

ALK-Abelló A/S currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for AKBLF.

What other companies compete with ALK-Abelló A/S?

Other companies that are similar to ALK-Abelló A/S include 180 Life Sciences, 3SBio, 60 Degrees Pharmaceuticals, Abcam and Adocia. Learn More about companies similar to ALK-Abelló A/S.

How do I contact ALK-Abelló A/S's investor relations team?

ALK-Abelló A/S's physical mailing address is Bøge Allé 6-8, Hørsholm, Capital Region. The company's listed phone number is 45.45.74.75.76. The official website for ALK-Abelló A/S is www.alk.net. Learn More about contacing ALK-Abelló A/S investor relations.